FCCC LOGO Faculty Publications
Paltser G , Liu XJ , Yantha J , Winer S , Tsui H , Wu P , Maezawa Y , Cahill LS , Laliberte CL , Ramagopalan SV , DeLuca GC , Sadovnick AD , Astsaturov I , Ebers GC , Henkelman RM , Salter MW , Dosch HM
TRPV1 Gates Tissue Access and Sustains Pathogenicity in Autoimmune Encephalitis
Molecular Medicine. 2013 Jan-Jun;19 :149-159
PMID: WOS:000328604200017    PMCID: PMC3745593   
Back to previous list
Abstract
Multiple sclerosis (MS) is a chronic progressive, demyelinating condition whose therapeutic needs are unmet, and whose pathoetiology is elusive. We report that transient receptor potential vanilloid-1 (TRPV1) expressed in a major sensory neuron subset, controls severity and progression of experimental autoimmune encephalomyelitis (EAE) in mice and likely in primary progressive MS. TRPV1(-/-) B6 congenics are protected from EAE. Increased survival reflects reduced central nervous systems (CNS) infiltration, despite indistinguishable T cell autoreactivity and pathogenicity in the periphery of TRPV1-sufficient and -deficient mice. The TRPV1(+) neurovascular complex defining the blood-CNS barriers promoted invasion of pathogenic lymphocytes without the contribution of TRPV1-dependent neuropeptides such as substance P. In MS patients, we found a selective risk-association of the missense rs877610 TRPV1 single nucleotide polymorphism (SNP) in primary progressive disease. Our findings indicate that TRPV1 is a critical disease modifier in EAE, and we identify a predictor of severe disease course and a novel target for MS therapy.
Notes
Paltser, Geoffrey Liu, Xue Jun Yantha, Jason Winer, Shawn Tsui, Hubert Wu, Ping Maezawa, Yuko Cahill, Lindsay S. Laliberte, Christine L. Ramagopalan, Sreeram V. DeLuca, Gabriele C. Sadovnick, A. Dessa Astsaturov, Igor Ebers, George C. Henkelman, R. Mark Salter, Michael W. Dosch, H-Michael